{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Skin+Cancer&page=117",
    "query": {
      "condition": "Metastatic Skin Cancer",
      "page": 117
    },
    "page_size": 10
  },
  "pagination": {
    "page": 117,
    "page_size": 10,
    "total_count": 2840,
    "total_pages": 284,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Skin+Cancer&page=118&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Skin+Cancer&page=116&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-22T21:15:21.265Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00570921",
      "title": "Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mara Chambers",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "45 Years and older · Female only"
      },
      "enrollment_count": 33,
      "start_date": "2008-04",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2017-02-23",
      "last_synced_at": "2026-11-22T21:15:21.265Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00570921"
    },
    {
      "nct_id": "NCT00049114",
      "title": "Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Inflammatory Breast Cancer",
        "Stage II Breast Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer"
      ],
      "interventions": [
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "tipifarnib",
          "type": "DRUG"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 62,
      "start_date": "2003-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-06-06",
      "last_synced_at": "2026-11-22T21:15:21.265Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00049114"
    },
    {
      "nct_id": "NCT00546104",
      "title": "Phase II Dasatinib Study in Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 31,
      "start_date": "2007-10",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2013-07-17",
      "last_synced_at": "2026-11-22T21:15:21.265Z",
      "location_count": 3,
      "location_summary": "West Palm Beach, Florida • Charlotte, North Carolina • Durham, North Carolina",
      "locations": [
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00546104"
    },
    {
      "nct_id": "NCT00960752",
      "title": "Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "gp100",
          "type": "DRUG"
        },
        {
          "name": "R848 gel",
          "type": "DRUG"
        },
        {
          "name": "MAGE-3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2010-05-20",
      "completion_date": "2020-07-20",
      "has_results": true,
      "last_update_posted_date": "2021-08-13",
      "last_synced_at": "2026-11-22T21:15:21.265Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00960752"
    },
    {
      "nct_id": "NCT06799065",
      "title": "First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Breast Cancer Recurrent",
        "Ovarian Cancer",
        "High-grade Serous Ovarian Carcinoma",
        "Triple Negative Breast Cancer",
        "sqNSCLC",
        "Squamous Non-small-cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "ATX-295",
          "type": "DRUG"
        },
        {
          "name": "ATX-295 and bevacizumab (or biosimilar)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Accent Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 218,
      "start_date": "2025-03-21",
      "completion_date": "2027-08-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-22T21:15:21.265Z",
      "location_count": 11,
      "location_summary": "Aurora, Colorado • Sarasota, Florida • Detroit, Michigan + 8 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06799065"
    },
    {
      "nct_id": "NCT05968144",
      "title": "Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostatic Neoplasm",
        "Survivorship",
        "Frailty",
        "Aging",
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Dietary recommendations",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Time-restricted eating",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2024-01-29",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-27",
      "last_synced_at": "2026-11-22T21:15:21.265Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05968144"
    },
    {
      "nct_id": "NCT06422455",
      "title": "Access to Genetic Testing in Underserved Patients With Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Carcinoma",
        "Male Breast Carcinoma",
        "Malignant Solid Neoplasm",
        "Metastatic Prostate Carcinoma",
        "Ovarian Carcinoma",
        "Pancreatic Exocrine Neoplasm",
        "Stage IVB Prostate Cancer American Joint Committee on Cancer v8",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Educational Intervention",
          "type": "OTHER"
        },
        {
          "name": "Electronic Health Record Review",
          "type": "OTHER"
        },
        {
          "name": "Genetic Counseling",
          "type": "OTHER"
        },
        {
          "name": "Interview",
          "type": "OTHER"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 800,
      "start_date": "2023-10-24",
      "completion_date": "2028-10-24",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-11-22T21:15:21.265Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Rochester, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06422455"
    },
    {
      "nct_id": "NCT00834678",
      "title": "Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "bendamustine",
          "type": "DRUG"
        },
        {
          "name": "erlotinib",
          "type": "DRUG"
        },
        {
          "name": "Maintenance erlotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2009-04",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2018-04-17",
      "last_synced_at": "2026-11-22T21:15:21.265Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00834678"
    },
    {
      "nct_id": "NCT00550654",
      "title": "Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Cancer",
        "Melanoma (Skin)",
        "Metastatic Cancer",
        "Ovarian Cancer",
        "Sarcoma",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        },
        {
          "name": "3-dimensional conformal radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "hypofractionated radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "image-guided radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "tomotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2007-10",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2017-01-13",
      "last_synced_at": "2026-11-22T21:15:21.265Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00550654"
    },
    {
      "nct_id": "NCT00003253",
      "title": "Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "antitumor drug screening assay",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Oncotech",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "1997-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-12-19",
      "last_synced_at": "2026-11-22T21:15:21.265Z",
      "location_count": 9,
      "location_summary": "Fountain Valley, California • Long Beach, California • Los Angeles, California + 5 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003253"
    }
  ]
}